Drug-Induced Liver Injury (DILI)

Hepatocellular Injury is one pattern of DILI where liver cells themselves are damaged. This is often reflected in elevated levels of liver enzymes like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in blood tests. For example, high doses of paracetamol (acetaminophen) can directly damage liver cells, leading to this type of injury.

Cholestatic Injury is another pattern where bile flow from the liver is impaired. This can result in elevated levels of alkaline phosphatase (ALP) and bilirubin in blood tests, as well as symptoms like jaundice (yellowing of the skin and eyes). Certain antibiotics, like co-amoxiclav, are known to sometimes cause cholestatic injury.

Idiosyncratic DILI refers to cases that are unpredictable and not related to the dose of the drug. These reactions are thought to involve complex interactions between the drug, the immune system, and individual genetic factors. This is why some people develop DILI from a drug that is safe for most others.

Direct Hepatotoxicity involves drugs that directly damage liver cells in a dose-dependent manner. The higher the dose, the greater the damage. An example is excessive alcohol consumption, which can lead to alcoholic hepatitis and cirrhosis.

The RUCAM (Roussel Uclaf Causality Assessment Method) scale is a tool used to assess the likelihood that a particular drug caused DILI. It considers factors like the timing of the drug exposure, the pattern of liver injury, and other possible causes. This helps doctors determine if a drug is indeed responsible for the liver damage.

Symptoms of DILI can be non-specific and may include fatigue, nausea, abdominal pain, jaundice, dark urine, and pale stools. Because these symptoms can be caused by many other conditions, DILI can be difficult to diagnose early. It's critical to consider medication history when evaluating patients with liver problems.

Certain populations are at higher risk of DILI, including older adults, people with pre-existing liver disease, and those taking multiple medications. These individuals require closer monitoring when starting new medications. For example, someone with hepatitis C may be more susceptible to liver damage from certain drugs.

The time frame for developing DILI can vary. Some drugs cause liver injury within days or weeks of starting treatment, while others may take months or even years to cause damage. Nitrofurantoin, used for long-term urinary tract infection prevention, is an example of a drug that can cause delayed DILI.

Treatment for DILI typically involves stopping the offending drug and providing supportive care. In severe cases, liver transplantation may be necessary. Early recognition and prompt discontinuation of the drug are crucial for improving outcomes.

Drug labels often include warnings about the risk of liver injury. These warnings are based on clinical trials and post-marketing surveillance data. It's important for both doctors and patients to be aware of these warnings and to monitor for signs of liver problems.

The gut-liver axis plays a role in DILI. The gut microbiota can influence the metabolism and toxicity of certain drugs, and disruptions in the gut microbiome can exacerbate liver injury. For example, mycotoxins, which are fungal metabolites found in food, can alter gut microbiota and contribute to liver disease.

The IIT Bombay study highlights that the location and duration of a drug's interaction with liver cell membranes can be more important than the extent of membrane disruption. Some drugs, like Teicoplanin, may stick to the membrane surface for longer periods, causing more harm than drugs that penetrate deeper into the membrane, like Oritavancin.